Tempus AI, Inc. (TEM)
| Market Cap | 6.91B |
| Revenue (ttm) | 562.02M |
| Net Income (ttm) | -224.48M |
| Shares Out | 164.83M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 708,084 |
| Open | 40.10 |
| Previous Close | 40.02 |
| Day's Range | 39.71 - 42.07 |
| 52-Week Range | 22.89 - 45.11 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.29 (+8.04%) |
| Earnings Date | Aug 6, 2024 |
About TEM
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to ph... [Read more]
Financial Performance
In 2023, Tempus AI's revenue was $531.82 million, an increase of 65.85% compared to the previous year's $320.67 million. Losses were -$265.96 million, -20.35% less than in 2022.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TEM stock is "Strong Buy." The 12-month stock price forecast is $45.29, which is an increase of 8.04% from the latest price.
News
Tempus to Report Second Quarter 2024 Financial Results on August 6
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesda...
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is ...
Lifeline Ambulance Saves $460,000 and Cuts Attrition by 58% with Blink's Employee Engagement Super-App
BOSTON--(BUSINESS WIRE)-- #EmployeeEngagement--Lifeline Ambulance has successfully reduced operational costs by $460,000 and attrition by 58% by using Blink's employee engagement platform.
Tempus Surpasses 500 Research Publications
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eig...
Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says
William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'
Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI
Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.
TD Cowen's Dan Brennan on why he's bullish on Tempus
Dan Brennan, senior analyst at TD Cowen, joins CNBC's 'The Exchange' to discuss his price target on Tempus, AI in diagnostics, and more.
Buy this healthcare company's stock because it's an AI play, analysts say
A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics sp...
Wall Street analysts bullish on genetic testing firm Tempus AI
Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more po...
IASA Opens Call for Content – June 2025 Annual Conference
TIMBERLAKE, N.C.--(BUSINESS WIRE)--The Call for Content for IASA's Xchange annual conference held June 8–10, 2025, in St. Louis, is now open.
American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company's PurISTSM algorithmic test has received a proprie...
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted...
SoftBank Group launches AI healthcare joint venture with Tempus AI
Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommend...
Revere Payments Named BigCommerce Preferred Technology Partner
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience.
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Admini...
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotec...
Tempus IPO: Stock price watched today as AI health-tech company starts Nasdaq trading
Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public.
Tempus soars 15% on the first day of trading, demonstrating investor appetite for a health tech with a promise of AI
Tempus, a genomic testing and data analysis company started by Eric Lefkosky, who previously founded Groupon, debuted on Nasdaq on Friday, rose about 15% on the opening
Tempus AI Surges in Nasdaq Debut Following IPO
Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq.
Tempus AI shares jump 8% in Nasdaq debut
Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.
Tempus AI CEO Eric Lefkofsky on going public: It's been an incredible journey
Tempus AI founder and CEO Eric Lefkofsky joins 'Squawk Box' to discuss taking the company public on Nasdaq later today, the origin of the company,
Tempus AI announces pricing of US IPO
SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
Tempus Announces Pricing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 pe...
Healthcare-technology company Tempus AI looks to raise $400 million in IPO
Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
Tempus AI seeks up to $6.1 bln valuation in US IPO
Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.